Source-grounded facts extracted from Cogent Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Cogent Biosciences, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-04-13 meeting.
“Votes For Votes Against Abstentions Broker Non-Votes Proposal 3. Advisory Vote on Executive Compensation 129,183,846 13,977,449 32,606 11,240,612”
Cogent Biosciences, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm at the 2026-04-13 meeting.
“Votes For Votes Against Abstentions Broker Non-Votes Proposal 2. Ratification of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm 154,001,553 399,367 33,593 0”
Cogent Biosciences, Inc. shareholders approved Election of Directors at the 2026-04-13 meeting.
“At the Annual Meeting, each of the Company’s director nominees was elected and each of the other proposals voted on were approved. The final voting results are set forth below. Votes For Votes Withheld Broker Non-Votes Proposal 1. Election of Directors • Chris Cain, Ph.D. 124,356,809 18,837,092 11,240,612 • Arlene Morris 120,180,517 23,013,384 11,240,612 • Todd Shegog 124,143,441 19,050,460 11,240,612”
Cogent Biosciences, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $97.4 million for the first quarter of 2026 compared to a net loss of $72.0 million for the first quarter o.
“On May 5, 2026, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the three months ended March 31, 2026.”
Cogent Biosciences, Inc. incurred convertible notes of $230,000,000 aggregate principal amount with U.S. Bank Trust Company, National Association at 1.625% per year maturing November 15, 2031.
“On November 18, 2025, Cogent Biosciences, Inc. (the “Company”) completed its previously-announced public offering (the “Offering”) of $230,000,000 aggregate principal amount of its 1.625% Convertible Senior Notes due 2031”
Cogent Biosciences, Inc. incurred lease obligation with BP THIRD AVENUE LLC maturing seven (7) years and ten (10) months from the Commencement Date.
“On September 5, 2025, Cogent Biosciences, Inc. (“Cogent”) and BP THIRD AVENUE LLC, an affiliate of Boston Properties (the “Landlord”), entered into a lease agreement (the “Lease”)”
Cogent Biosciences, Inc. incurred term loan of $50.0 million with SLR Investment Corp. at 4.75% plus the greater of (i) one-month term SOFR, and (ii) 4.15% per annum maturing June 1, 2030.
“Security Agreement provides for a non-dilutive term loan facility (the “Credit Facility”) of up to an aggregate principal amount of $400.0 million, of which a first tranche of $50.0 million was fully funded on the Closing Date, with future tranches at the Company’s election subject to achievement of milestones consisting of (a) a second tranche of $25.0 million”
Cogent Biosciences, Inc.: Stockholders approved an amendment to the certificate of incorporation to provide for officer exculpation from liability, which was filed and became effective on June 4, 2025 (effective 2025-06-04).
“At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to provide for exculpation from liability for officers of the Company, as described in more detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 22, 2025 (the “Amendment”). On June 4, 2025, the Company filed a Certificate of Amendment to the Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect the Amendment, which became effective immediately upon such filing.”
Cogent Biosciences, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $58.3 million.
“Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024.”
Cogent Biosciences, Inc. reported financial results for the quarter and year ended December 31, 2023.
“On February 26, 2024, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter and year ended December 31, 2023.”
Cogent Biosciences, Inc.: Filed Certificate of Designation for Series B Non-Voting Convertible Preferred Stock, establishing the powers, preferences, rights, and limitations of the new series (effective 2024-02-14).
“On February 14, 2024, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware (the “ Certificate of Designation ”) in connection with the Private Placement.”
Cogent Biosciences, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $225 million (effective 2024-02-13).
“On February 13, 2024, Cogent Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with certain institutional and accredited investors (each, a “ Purchaser ” and collectively, the “ Purchasers ”).”
Cogent Biosciences, Inc. reported financial results for the third quarter ended September 30, 2023.
“On November 2, 2023, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended September 30, 2023.”
Cogent Biosciences, Inc. reported the second quarter ended June 30, 2023 results: net income $44.1 million.
“Net loss was $44.1 million for the second quarter of 2023”
Cogent Biosciences, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Jefferies LLC, Piper Sandler & Co. and Guggenheim Securities, LLC, as the representatives of the underwriters valued at $150 million (effective 2023-06-06).
“On June 6, 2023, Cogent Biosciences, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, Piper Sandler & Co. and Guggenheim Securities, LLC, as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 12,500,000 shares of the Company’s common stock at a public offering price of $12.00 per share (the “Offering”).”
Cogent Biosciences, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm.
“Proposal 3. Ratification of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm 65,536,975 26,688 2,800 0”
Cogent Biosciences, Inc. shareholders approved Approval of an increase of 6,000,000 shares reserved for issuance under the 2018 Plan.
“Proposal 2. Approval of an increase of 6,000,000 shares reserved for issuance under the 2018 Plan 40,805,846 23,427,202 3,845 1,329,570”
Cogent Biosciences, Inc. shareholders approved Election of Directors.
“Proposal 1. Election of Directors • Chris Cain, Ph.D. 52,182,072 12,054,821 1,329,570 • Arlene M. Morris 51,995,228 12,241,665 1,329,570 • Todd Shegog 51,200,110 13,036,783 1,329,570”
Cogent Biosciences, Inc. reported the first quarter ended March 31, 2023 results: net income $38.6 million.
“Net loss was $38.6 million for the first quarter of 2023 compared to a net loss of $30.6 million for the first quarter of 2022.”
Cogent Biosciences, Inc. reported financial results for the fourth quarter and full year of 2022.
“On March 14, 2023, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter and year ended December 31, 2023.”
Cogent Biosciences, Inc. reported the quarter ended September 30, 2022 results: net income $35.1 million.
“Net Loss: Net loss was $35.1 million for the th”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.